MedWatch

Saniona clears obstacle ahead of new trial

The US health authorities have now received the all of the requested documentation for the capsule version of the biotech company's candidate Tesomet. Saniona's plans to begin a clinical trial with the drug before the end of year thus remain unchanged.

Photo: Saniona / PR

After dialog with the US Food and Drug Administration (FDA), the biotech company Saniona is sticking to its plans to initiate a phase IIb trial of its drug Tesomet before the end of the year, it reports in a press release.

Saniona has finished submitting additional information to the authority, which the FDA requested after the company swapped out the tablet-based version of its candidate for a capsule ahead of its planned trial.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs